Retinoid Resistance in Leukemic Cells

References

• Strickland S., Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1978; 15: 393–403
   PubMed Web of Science ®Google Scholar
• Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem. Biophys. Acta 1980; 605: 33–91
   PubMed Web of Science ®Google Scholar
• Douer D., Koeffler H. P. Retinoic acid enhances colony‐stimulating factor‐induced clonal growth of normal human myeloid progenitors in vitro. Exp. Cell Res. 1982; 138: 193–198
   PubMed Web of Science ®Google Scholar
• Douer D., Koeffler H. P. Retinoic acid: Induction of the clonal growth of human myeloid leukemic cells. J. Clin. Invest 1982; 69: 277–283
   PubMed Web of Science ®Google Scholar
• Breitman T. R., Selonick S. E., Collins S. J. Induction of differentiation of the human promyelocytic leukemic cell line (HL‐60) by retinoic acid. Proc. Natl. Acad. Sci. USA 1980; 77: 2936–2940
   PubMed Web of Science ®Google Scholar
• Koeffler H. P. Induction of differentiation of human acute myelogenous leukemic cells: Therapeutic implications. Blood 1983; 62: 709–721
   PubMed Web of Science ®Google Scholar
• Giguere V., Ong E. S., Segui P., Evans R. M. Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330: 624–629
   PubMed Web of Science ®Google Scholar
• Petkovick M., Brand N. J., Krust A., Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 345: 444–450
   Web of Science ®Google Scholar
• Mangelsdorf D. J., Ong E. S., Dyck J. A., Evans R. M. A nuclear receptor that identifies a novel retinoic acid receptor pathway. Nature 1990; 345: 224–229
   PubMed Web of Science ®Google Scholar
• Leid M., Kastner P., Lyons R., Nakshatri H., Saunders M., Zacharewski T., Chen J. Y., Staub A., Garnier J. M., Mader S., Chambon P. Purification, cloning, and RXR identify of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992; 68: 377–395
   PubMed Web of Science ®Google Scholar
• Yang N., Schule R., Mangelsdorf D. J., Evans R. M. Characterization of DNA binding and retinoic acid binding properties of the retinoic acid receptor. Proc. Natl. Acad. Sci. USA 1992; 88: 3559–3563
   Web of Science ®Google Scholar
• Levin A. A., Sturzenbecker L. J., Kazmer S., Bosakowski T., Huselton C., Allenby G., Speck J., Kratzeisen C., Rosenberger M., Lovey A., Grippo J. F. 9‐cisretinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature 1992; 355: 359–361
   PubMed Web of Science ®Google Scholar
• Heyman R. A., Mangelsdorf D. J., Dick J. A., Stein R. B., Eichele G., Evans R. M., Theller C. 9‐cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68: 397–406
   PubMed Web of Science ®Google Scholar
• Leid M., Kastner P., Durand B., Krust A., Leroy P., Lyons R., Mendelsohn C., Nagpal S., Nakshatri H., Reibel C., Saunders M., Chambon P. Retinoic acid signal transduction pathways. Ann. NY. Acad. Sci. 1993; 684: 19–34
   PubMed Web of Science ®Google Scholar
• Sakashita A., Kizaki M., Pakkala S., Schiller G., Tsuruoka N., Tanosaki R., Cameron J. F., Dawson M. I., Koeffler H. P. 9‐cis retinoic acid: Effects on normal and leukemic hematopoiesis in vitro. Blood 1993; 81: 1009–1016
   PubMed Web of Science ®Google Scholar
• Kizaki M., Ikeda Y., Tanosaki R., Nakajima H., Morikawa M., Sakashita A., Koeffler H. P. Effects of novel retinoic acid compound, 9‐cis retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor (RAR)‐α and retinoid X receptor (RXR)‐α RNA by HL‐60 cells. Blood 1993; 82: 3592–3597
   PubMed Web of Science ®Google Scholar
• Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all‐trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., Ballarini P., Berger R., Fenaux P., Degos L. All‐trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr., Frankel S. R., Miller W. H., Jr., Sheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M. S., Dmitrovski E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all‐trans retinoic acid). N. Eng. J. Med. 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr., The H., Wang Z. Y., Degos L. Acute promyelocytic leukemia. N. Eng. J. Med. 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Chen Z. X., Xue Y. Q., Zhang R., Tao R. F., Xia X. M., Li C., Wang W., Zu W. Y., Yao X. Z., Ling B. J. A clinical and experimental study on all‐trans retinoic acid‐treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Lanotte M., Martin‐Thouvenin V., Najiman S., Balerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15; 17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086
   PubMed Web of Science ®Google Scholar
• Duprez E., Ruchaud S., Houge G., Martin‐Thouvenin V., Valensi F., Kastner P., Berger R., Lanotte M. A retinoid acid “resistant” t(15:17) acute promyelocytic leukemia cell line: Isolation, morphological, immunological, and molecular features. Leukemia 1992; 6: 1281–1287
   PubMed Web of Science ®Google Scholar
• Kizaki M., Matsushita H., Takayama N., Muto A., Ueno H., Awaya N., Kawai Y., Asou H., Kamada N., Ikeda Y. Establishment and differentiation of a novel acute promyelocytic leukemia cell line (UF‐1) with retinoic acid resistant features. Blood 1996; 88: 1824–1833
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 1993; 82: 1949–1953
   PubMed Web of Science ®Google Scholar
• Muindi J. R. F., Frankel S. R., Huselton C., Degrazia F., Garland W. A., Young C. W., Warrell R. P., Jr. Clinical pharmacology of oral all‐trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992; 52: 2138–2142
   PubMed Web of Science ®Google Scholar
• Muindi J. R. F., Frankel S. R., Miller W. H., Jr., Jakubowski A., Scheinberg D. A., Young C. W., Dmitrowski E., Warrell R. P., Jr. Continuous treatment with all‐trans retinoic acid causes a progressive decrease in plasma concentrations: Implications for relapse and “resistance” in acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Delva L., Comic M., Balitrand N., Guidez F., Miclea J. ‐M., Delmer A., Teillet F., Fenaux P., Castaigne S., Degos L., Chomienne C. Resistance to all‐trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175–2181
   PubMed Web of Science ®Google Scholar
• Roberts A. B., Lamb L. C., Sporn M. B. Metabolism of all‐trans retinoic acid in hamster liver microsomes: Oxidation of 4‐hydroxy‐to 4‐keto retinoic acid. Arch. Biochem. Biophys. 1980; 199: 374–383
   PubMed Web of Science ®Google Scholar
• Rigas J. R., Francis P. A., Muindi J. R. F., Kris M. G., Huselton C., DeGrazia F., Orazem J. P., Young C. W., Warrell R. P., Jr. Constitutive variability in the phar‐macokinetics of the natural retinoid, all‐trans retinoic acid, and its modulation by ketoconazole. J. Natl. Cancer Inst. 1993; 85: 1921–1926
   PubMed Web of Science ®Google Scholar
• Kizaki M., Ueno H., Yamazoe Y., Shimada M., Takayama N., Muto A., Matsushita H., Nakajima H., Morikawa M., Koeffler H. P., Ikeda Y. Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P‐450 and P‐glycoprotein. Blood 1996; 87: 725–733
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12: 1–51
   PubMed Web of Science ®Google Scholar
• Vecchini F., Lenoir‐Viale M. C., Cathelineau C., Magdalou J., Bernard B. A., Shroot B. Presence of a retinoid responsive element in the promotor region of the human cytochrome P4501A1 gene. Biochem. Biophys. Res. Commun. 1994; 201: 1205–1212
   PubMed Web of Science ®Google Scholar
• Jaiswal A. K., Gonzalez F. J., Nebert D. W. Human dioxin‐inducible cytochrome PI‐450: Complementary DNA and amino acid sequence. Science 1985; 228: 80–83
   PubMed Web of Science ®Google Scholar
• Chen C., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M., Roninson I. B. Internal duplication and homology with bacterial transport proteins in the mdr l (P‐glycoprotein) gene from multidrug‐resistant human cells. Cell 1986; 47: 381–389
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170– to 180‐kDa glycoprotein specific to drug‐resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Paietta E., Andersen J., Racevskis J., Gallagher R., Bennett J., Yunis J., Cassileth P., Wiernik P. H. Significantly lower P‐glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunologiocal, molecular and functional analyses. Leukemia 1994; 8: 968–973
   PubMed Web of Science ®Google Scholar
• Drach D., Zhao S., Drach J., Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukemia. Br. J. Haematol. 1995; 90: 369–374
   PubMed Web of Science ®Google Scholar
• Robertson K. A., Emami B., Collins S. J. Retinoic acid‐resistant HL‐60R cells harbor a point mutation in the retinoic acid receptor ligand‐binding domain that confers dominant negative activity. Blood 1992; 80: 1885–1889
   PubMed Web of Science ®Google Scholar
• Li Y. P., Said F., Gallagher R. E. Retinoic acid‐resistant HL‐60 cells exclusively contain mutant retinoic acid receptor‐a. Blood 1994; 83: 3298–3302
   PubMed Web of Science ®Google Scholar
• Gallagher R. E., Bilello P. A., Ferrari A. C., Chang C. S., Yen R. W. C., Nikols W. A., Muly E. C., III. Characterization of differentiation inducer‐resistant HL‐60 cells. Leuk. Res. 1985; 9: 967–986
   PubMed Web of Science ®Google Scholar
• Morosetti R., Grignani F., Liberatore C., Pelicci P. G., Schiller G. J., Kizaki M., Bartram C. R., Miller C. W., Koeffler H. P. Infrequent alterations of the RARα gene in acute myelogenous leukemias, retinoic acid‐resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines. Blood 1996; 87: 4399–4403
   PubMed Web of Science ®Google Scholar